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Staphylococcus aureus is a pathogen often found in pneumonia and sepsis. In the context of the resistance of
this organism to conventional antibiotics, an understanding of the regulation of natural endogenous antimi-
crobial molecules is of paramount importance. Previous studies have shown that both human and mouse airways
express a variety of these molecules, including defensins, cathelicidins, and the four-disulfide core protein secretory
leukocyte protease inhibitor. We demonstrate here by culturing mouse tracheal epithelial cells at an air-liquid
interface that, despite the production of Defb1, Defb14, and Defr1 in this system, these cells are unable to clear S.
aureus when exposed to this respiratory pathogen. Using an adenovirus (Ad)-mediated gene transfer strategy, we
show that overexpression of elafin, an anti-elastase/antimicrobial molecule (also a member of the four-disulfide core
protein family), dramatically improves the clearance of S. aureus. In addition, we also demonstrate that this
overexpression is efficient in vivo and that intratracheal instillation of Ad-elafin significantly reduced the lung
bacterial load and demonstrates concomitant anti-inflammatory activity by reducing neutrophil numbers and
markers of lung inflammation, such as bronchoalveolar lavage levels of tumor necrosis factor and myeloperoxidase.
These findings show that an increased antimicrobial activity phenotype is provided by the elafin molecule and have
implications for its use in S. aureus-associated local and systemic infections.
Staphylococcus aureus infections are closely associated with
pneumonia and sepsis, particularly in nosocomial infections
(12, 13). This organism can often cause primary pneumonias,
in young adults and patients with cystic fibrosis (5, 8, 9). Al-
though pulmonary infections with S. aureus could until recently
be controlled with aggressive antibiotic therapy, the increasing
association of S. aureus with antimicrobial resistance has be-
come a major concern for clinicians.
In that context, endogenous antimicrobial molecules
(AMMs) are gathering interest as alternative microbicidal
agents since they are thought to be less likely to induce bac-
terial resistance than conventional antibiotics (10). This class
of molecules includes defensins, cathelicidins, and the four-
disulfide core proteins secretory leukocyte protease inhibitor
and elafin (29–31). In parallel with human airways, respiratory
tract epithelia of mice (a useful species in which to model lung
infections) have been shown to express -defensin molecules,
including Defb1 (18), Defb2 (19), Defb3 (2), Defb4 (14), Def
b6 (38), Defr1 (21), and the cathelicidin CRAMP (24).
Although little is known about the in vivo activity of these
molecules against S. aureus, we have shown that chemically
synthesized -defensin Defb1and Defr1 murine peptides have
antimicrobial activity in vitro against this microorganism (18,
21). However, deletion of Defb1 by gene targeting did not lead
to increased airway retention of this pathogen after exposure in
vivo (20, 22). This suggests that the peptide is either redundant
or not crucial in innate immunity against S. aureus in the
airways. To investigate innate defenses against S. aureus at the
mucosal surface of the airways and to facilitate screening of
other potentially important AMMs, we used primary cultures
of differentiated mouse tracheal epithelia (at an air-liquid inter-
face [ALI]) as previously described (4). We demonstrate here that
Defb1, Defr1, and Defb14 (the orthologue of human -defensin 3,
DEFB103), which display potent activity against S. aureus in vitro
(17), are expressed in these epithelial cell cultures. In addition, we
show that despite expressing a repertoire of peptides capable of
killing S. aureus in vitro, primary ALI cultured cells are unable to
clear this respiratory pathogen. In contrast, we show there that
adenovirus (Ad)-mediated overexpression of human elafin/skin-
derived antileucoprotease/trappin-2 (16, 31, 34, 37), a 9.9-kDa
neutrophil elastase inhibitor with antimicrobial activity against S.
aureus and Pseudomonas aeruginosa (when added as a purified
molecule, leads to killing of S. aureus both in vitro and in vivo in
a murine acute lung infection model. This demonstrates that
elafin overexpression may have potential therapeutic benefit
against S. aureus infections.
MATERIALS AND METHODS
Recombinant replication-deficient Ad constructs. Two E1-partially E3-deleted
type 5 recombinant replication-deficient adenoviruses were used. The Ad-LacZ
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construct was a gift from J. Gauldie and F. Graham (1), whereas the Ad-elafin
construct was generated as described before (28).
Bacteria. S. aureus C1705 (a clinical strain [9, 18]) was grown initially as
colonies on Colombia agar (Unipath, Basingstoke, United Kingdom) and then in
10 ml of tryptone soy broth (Unipath) overnight at 37°C in an orbital shaker
(Gallenkamp; Fisher Scientific, Loughborough, United Kingdom) at 200 rpm at
room temperature. The resulting suspension was centrifuged at 3,000 rpm for 15
min at room temperature. The supernatant was discarded, and the pellet resus-
pended in 10 ml of phosphate buffer (8 mM K2HPO4, 2 mM KH2PO4). Suspen-
sions were adjusted with phosphate buffer to an A590 of 1.50, yielding an esti-
mated bacterial concentration of 109 CFU/ml, in accordance with predetermined
growth curves.
Serial dilutions were performed with phosphate buffer to obtain the desired
concentration of viable bacteria (see below).
Mouse epithelial cell culture. Female C57BL/6 or BALB/c murine primary
tracheal epithelial cells were generated and grown on semipermeable mem-
branes at an ALI according to our previously published method (4). Briefly,
tracheae were excised and severed at the proximal limit of the thyroid cartilage
and at the junction of the main bronchi. The thyroid gland and other adherent
tissues were removed before cutting tracheae longitudinally. Dissociated cells
from two tracheae (ca. 4  105 cells) were seeded onto one semipermeable
support membrane, precoated with 0.5 mg of collagen/ml (24-well plate inserts,
0.4-m pore size; Corning Costar) in 0.2 ml of culture medium (1:1 Dulbecco
modified Eagle medium-Ham’s F-12 medium containing 100 U of penicillin and
100 g of streptomycin/ml). Cells were incubated at 37°C in 6% CO2 for 3 days.
On day 4, medium bathing the apical cell surface was removed, along with any
cell debris, and the medium on the outside of the insert replaced with 0.6 ml of
Ultroser G (USG) medium. Cells were verified as confluent, with tight junctions,
by monitoring transepithelial resistance, as described previously (4). Only cul-
tures with high (12-k/cm2) resistances were used. In addition, light micros-
copy confirmed the presence of cells with epithelial morphology and demon-
strated the appearance of beating cilia. In selected cases, lipopolysaccharide
(Escherichia coli O26:B6 [Sigma]) was added to the surface of the cells at 80
g/insert and incubated for 2 h at 37°C with 6% CO2. After lipopolysaccharide
(LPS) incubation, the cells were harvested and RNA was extracted.
RT-PCR. Reverse transcription-PCR (RT-PCR) was carried out as previously
described (4). Briefly, total RNA was isolated from cells or tissues collected by
using RNAzol B as described by the manufacturer (Biogenesis). cDNA synthesis
was achieved by using a first strand cDNA synthesis kit (Roche), and the result-
ant cDNA was used as a template in PCRs with the following primers (forward
and reverse): Defb1, 5-CCAGCTGCCCATCTAATACC-3 and 5-AATCCAT
CGCTCGTCCTTTA-3; Defb14, 5-TCTTGTTCTTGGTGCCTGCT-3 and 5-
TTCTTCTTTCGGCAGCATTT-3; and Defr1, 5-ATTTCTCCTGGTGCTGC
TGT-3 and -GGTTTGCAGGATCTTTGTC-3.
The following conditions were used for PCR: denaturation at 94°C for 3 min,
followed by 45 cycles of 94°C for 30 s; annealing at temperatures of 54°C for
Defb1, 54°C for Defb14, and 60°C for Defr1 for 30 s, with extension at 72°C for
1 min. The amplified products were analyzed on 2% agarose gels by electro-
phoresis. To confirm RNA amplification of defensin genes, the primers were
situated in exons 1 and 2. For elafin RT-PCR, controls were included without
reverse transcriptase, and RNA was DNase treated prior to cDNA synthesis
according to established methods. Template cDNA was amplified with the prim-
ers 5-CTGTAGATTTTATCAGACTGAAGAG-3 and 5-GTCAAGGGCAT
ATCCAACAACAAA-3 for hypoxanthine phosphoribosyl transferase (Hprt) as
a positive control. Southern blotting was performed with Hybond-N membranes
(Amersham), and hybridization was carried out with internal radiolabeled oli-
gonucleotide probes (Defb1, 5-CTGTTGTAAGAGCTGA-3; Defb14, 5-GGA
CGCATTCCTACCAAAAA-3; and Defr1, 5CTTATGCCTAAGGCCAATGC
3) for 16 h at 48°C. Filters were washed twice in 0.6 M NaCl–0.06 M trisodium
citrate (standard saline citrate) plus 0.5% sodium dodecyl sulfate for 30 min
before being exposed to photographic film.
Adenovirus infection of epithelial cells. In order to increase the efficiency of
infection of mouse tracheal epithelial cells (estimated number  400,000 per
insert), Ad infections (multiplicity of infection [MOI] of 100) were carried out in
the presence of CaPO4 precipitates (final concentration 5.8 mM Ca2 and 0.86
mM PO4) generated by adding CaCl2 (4 mM final concentration) to minimal
essential Eagle medium (MEEM), a medium with a high enough PO4 concen-
tration to allow for the generation of these precipitates (6). Alternatively, Ad
infections were carried out in USG medium. Cells were incubated with these
infection media in a total volume of 250 l for 45 min at 37°C. Cells were washed
twice with phosphate-buffered saline (PBS) and then incubated for 18 to 20 h at
37°C in the absence of medium bathing the apical surface.
To assess the Ad infection efficiency, Ad-LacZ-infected epithelial cell layers
were fixed for 10 min with a solution comprising 0.2% glutaraldehyde, 0.8%
formaldehyde, and 2 mM MgCl2 (in PBS). Fixative was discarded, and 200 l of
staining solution [5 mM K4Fe(CN)6, 5 mM K3 Fe3 (CN)6, 2 mM MgCl2, 0.05%
Triton X-100, 0.5 mg of X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyrano-
side)/ml (in PBS)] was added for 5 h at 37°C. Cells were washed with PBS to
remove residual stain, air dried, and photographed.
Ad-elafin quantification and antibacterial activity in vitro. Mouse tracheal
epithelial cells were infected with Ad-elafin (and relevant controls) in MEEM
containing CaPO4 precipitates (see above) and in the absence of antibiotics.
After 18 to 20 h at 37°C (see above), 20 nl of either phosphate buffer or a C1705
S. aureus suspension (107 CFU/ml) was added to the cells with the use of a
special Hamilton precision syringe (Hamilton Company, Reno, NV), followed by
incubation for 3 h at 37°C. Cell inserts were washed with both 105 l of phos-
phate buffer and 105 l of phosphate buffer–0.5% Triton X-100. These two
washes were then pooled and centrifuged at 8,000 rpm for 10 min. Supernatants
were used for elafin quantitation by enzyme-linked immunosorbent assay
(ELISA) (27), whereas bacterial cell pellets were suspended in PBS and used for
bacterial counts on Colombia agar. Agar plates were incubated overnight at 37°C
prior to colony counting. Values represent the mean 	 the standard error of
three experiments, each performed in triplicate. (Significant differences [P 

0.05] compared to Ad-lacZ-infected cells are indicated in Table 1.)
In vivo studies. Female C57BL/6 mice between 6 and 8 weeks old (Harlan
Olac, Bicester, United Kingdom) were treated intratracheally (as described in
reference 33) with 40 l of Ad-LacZ (adenovirus control) or Ad-elafin (3  107
PFU in both cases). After 5 days, 4  107 CFU of S. aureus (in 40 l) were
administered via the same route. This bacterial dose was shown in previous pilot
experiments to produce a substantial inflammatory response in the lung. At 24 h
after the bacterial administration, mice were euthanized and bronchoalveolar
lavage (BAL) performed (two serial instillations of 0.4 ml of PBS). BAL fluid
(BALF) was centrifuged 10 min at 4,000  g; supernatants were stored at 20°C
until further use, whereas each cell pellet was resuspended in 100 l of PBS. Cell
counting (with a hemocytometer) and cytospins (300 rpm for 3 min at room
temperature) were then performed. After BALF was recovered, the lungs were
harvested for either RNA preparation (storage in RNA later [Sigma]), histology,
or bacterial counts. For the latter, half lungs were homogenized in 2 ml of PBS
by using a tissue homogenizer (OMNI H International; Camlab), and homog-
enates were further diluted 10-fold with PBS. A total of 100 l of the diluent was
plated on Colombia agar plates, which were incubated at 37°C for 24 h.
ELISAs. ELISA analyses to detect murine tumor necrosis factor alpha
(TNF-) were performed by using the R&D Duoset kit (Abingdon, Oxon,
United Kingdom) in accordance with the manufacturer’s instructions.
Human elafin was measured by ELISA as described previously (27).
Protein quantification. Protein was measured by using the bicinchoninic acid
method (Pierce) with purified albumin (Pierce) as the standard.
MPO measurement. A total of 40 l of BAL fluid was incubated with 60 l of
TMB (3,3,5,5-tetramethylbenzidine substrate; 0.1 mg/ml in 0.1 M sodium ace-
tate-citrate buffer [pH 4.9]) containing 0.015% H2O2 (final concentration). After
5 min, the reaction was stopped with concentrated H2SO4, and the absorbance
was read at 450 nm (reference filter 560 nm) in a microtiter plate reader (MRX
II microtiter plate; Dynex Technologies).
Statistical analysis. Statistical analyses used either Student t tests or Mann-
Whitney tests.
RESULTS
Murine defensin expression in murine primary epithelial
cells. RNA was prepared from C57BL/6 tracheal inserts as
detailed in Materials and Methods, and RT-PCR was per-
formed with primers for Hprt (house keeping gene), as well as
for the three murine -defensin genes relevant to antimicrobial
activity against S. aureus. Figure 1 demonstrates that murine
C57BL/6 tracheal cells express Defb1, the mouse orthologue of
human DEFB1, and Defb14, the mouse orthologue of
DEFB103. We also show for the first time that Defr1 is ex-
pressed in murine epithelial cells. There is no evidence for
significant upregulation of these genes after LPS exposure.
Innate antimicrobial activity of murine epithelial cells
against S. aureus. We were interested in examining whether
any difference in bacterial killing was evident between BALB/c
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and C57BL/6 mice since they have a polymorphism in one of
their -defensin genes. BALB/c has Defb8, a classic six cys-
teine -defensin, whereas C57BL/6 has a polymorphic allele
with three nucleotide and amino acid changes that results in a
five-cysteine -defensin termed Defr1. This molecule has a
novel structure, which when made synthetically has potent
antibacterial activity (3). Despite the expression of -defensins
in C57BL/6 tracheal cells, neither these cells nor cells derived
from BALB/c mice were able to inhibit the growth of an ap-
proximately 200 CFU S. aureus inoculum (20 nl of a 107-
CFU/ml S. aureus suspension) (Fig. 2). This was considered
already as a very small inoculum (identical to that used by
Smith et al. [36]), and no attempt was made to further reduce
that dose. Indeed, at 3 h postinoculation, an average of 3,077
and 2,050 CFU were recovered from C57BL/6 and BALB/c
cells, respectively, compared to 329 in the original inoculum.
This clearly demonstrates that, far from being bacteriostatic or
bactericidal, the tracheal epithelium was able to promote S.
aureus growth under these conditions.
With this observation in mind, we examined whether recom-
FIG. 1. Expression of defensin genes in mouse primary tracheal epithelial cells. RNA was prepared from female C57BL/6 tracheal epithelial
cells (unstimulated or stimulated with LPS for 30 min), and RT-PCR was performed as detailed in Materials and Methods with primers for three
murine -defensin genes (Defb1, Defb14, and Defr1) and for the housekeeping gene Hprt. In the negative control lane (ve control), RNA was
not included in the RT-PCR mixture. (a) Ethidium bromide analysis; (b) Southern blot analysis.
FIG. 2. Endogenous antimicrobial activity of murine C57BL/6- and BALB/c-derived tracheal cells. A 200-CFU inoculum of S. aureus (20 nl of
either phosphate buffer or of a C1705 S. aureus suspension [107 CFU/ml]) was applied to inserts of either C57BL/6- or BALB/c-derived tracheal
epithelial cells, as described in Materials and Methods. Inserts were washed with 105 l of phosphate buffer and 105 l of phosphate buffer–0.5%
Triton X-100. Washes were pooled, followed by centrifugation at 8,000 rpm for 10 min, and the pellets were used for bacterial counts on nutrient
agar plates at 37°C. Values represent means 	 the standard errors of three experiments, each performed in triplicate (three inserts).
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binant adenovirus (Ad)-mediated overexpression of human
elafin, an antimicrobial molecule with no ortholog in mice, was
able to limit S. aureus growth in vitro and in vivo.
Optimization of infection of murine C57BL/6 epithelial cells
with Ad vectors. We first tested the Ad expression system by
using the E. coli -galactosidase reporter gene (Ad-LacZ).
Because others have reported poor adenoviral gene transfer to
airway epithelia due to low apical expression of the coxsackie/
adenovirus receptor (26), we used a method incorporating the
use of CaPO4 precipitates in the infection protocol in the
present study, as previously investigated (6).
Indeed, we show here (Fig. 3) that generation of CaPO4
precipitates in MEEM (a medium particularly well suited for
the generation of the latter due to its high concentration of
PO4 ions) containing Ad-LacZ significantly increased (two- to
threefold) the efficiency of infection of murine C57BL/6 tra-
cheal cells compared to Ad-LacZ infection in the USG me-
dium usually used for these cells (Fig. 3, compare panels D and
C). This amended protocol, with MEEM as the medium of
choice, was therefore used for all subsequent experiments.
Neither CaPO4- nor Ad-mediated cytotoxicity was detected by
trypan blue exclusion (not shown).
In vitro antibacterial activity of Ad-elafin against S. aureus.
Having established the conditions for optimal Ad infection of
murine C57BL/6 tracheal cells, we infected these cells with
Ad-elafin and used Ad-LacZ as an Ad control. Figure 4 shows
that, in accordance with all our previous studies (28, 30, 32),
murine cells do not produce an elafin-related protein since our
ELISA did not detect a cross-reacting species from untreated
cells or cells treated with Ad-LacZ. In contrast, Ad-elafin in-
fection induced the expression and secretion of very high levels
of human elafin (right panel). This level correlated with an
efficient reduction of S. aureus numbers (left panel, P 0.005).
In vivo antibacterial activity of Ad-elafin against S. aureus.
When studying antimicrobial activity against P. aeruginosa
(33), we have shown that Ad-LacZ was a useful Ad vector
control which, by itself, did not induce a detectable increase in
lung inflammation in comparison to PBS treatment. This lack
of overt inflammation caused by Ad-LacZ is most probably due
to the very low dose of Ad used in our study (3  107 PFU). In
FIG. 3. Optimization of infection of murine C57BL/6 tracheal cells with Ad-LacZ. Female C57BL/6 mouse tracheal epithelial cells cultured on
inserts (see above) were infected with Ad-LacZ at an MOI of 100, in the presence or absence of CaPO4 precipitates (final concentration of 5.8
mM Ca2 and 0.86 mM PO4) in MEEM or USG medium. Cells were incubated with this infection medium in a total volume of 250 l for 45 min
at 37°C. Cells were then washed twice with PBS and incubated for 18 to 20 h at 37°C in the absence of media bathing the apical surface. (A) No
Ad, USG medium; (B) no Ad, MEEM plus CaPO4; (C) Ad-LacZ, USG medium; (D) Ad-LacZ, MEEM plus CaPO4.
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the present study we compared two experimental groups, Ad-
LacZ (3  107 PFU) plus S. aureus and Ad-elafin (3  107
PFU) plus S. aureus, and one control group, PBS-PBS; the
latter served as a control for potential background S. aureus
commensals and contamination in the laboratory.
As expected and in keeping with our previous studies (and
present in vitro data), no elafin mRNA was detected by RT-
PCR in mice receiving Ad-LacZ or PBS, demonstrating that
the band detected in the Ad-elafin–S. aureus group (Fig. 5,
upper right) was specific to the human elafin transgene. This
elafin expression was associated with a reduction in the num-
ber of recovered S. aureus in the BALF of Ad-elafin-treated
mice, compared to mice given Ad-LacZ (Fig. 5, left panel; P 
0.038). As expected, no bacteria were recovered in the mice
treated twice with PBS.
Modulation of in vivo inflammatory responses by Ad-elafin
gene transfer. When inflammatory cell profiles in BALF were
studied, compared to the PBS/PBS group, unsurprisingly, both
the Ad-LacZ plus S. aureus and the Ad-elafin plus S. aureus
groups showed increased numbers of total inflammatory cells,
particularly neutrophils (P  0.02 and 0.013, respectively).
However, no statistically significant differences in cellular pro-
files were observed between the Ad-LaZ plus S. aureus and
Ad-elafin plus S. aureus groups (data not shown). Interestingly,
when the Ad-elafin plus S. aureus group was considered in
isolation, there was a strong negative correlation between BAL
elafin levels and neutrophil numbers (Fig. 6, r  0.63, P 
0.069), suggesting that elafin may be associated in this model
with a reduction in neutrophil numbers. Also, MPO levels,
used as a marker of neutrophil activation, were lower in the
Ad-elafin plus S. aureus group, although the difference did not
reach statistical significance. A similar reduction (statistically
significant) in the proinflammatory mediator TNF- was noted
in the Ad-elafin–S. aureus group, compared to the Ad-LacZ–S.
aureus group (Table 1). When total protein levels were mea-
sured as an index of blood and/or alveolar barrier disruption,
levels were lower in the PBS-PBS group compared to the
Ad-groups, but within these there was a trend toward reduc-
tion of protein levels in the Ad-elafin–S. aureus group. Mirror-
ing these data, blinded histological analysis showed neutro-
philic inflammatory foci in the Ad-LacZ-treated animals,
which were reduced in the Ad-elafin-treated mice. Quantifica-
tion of neutrophils in whole lung sections is also given (repre-
sentative sections are shown in Fig. 7).
DISCUSSION
S. aureus is a major human pathogen associated with local-
ized and systemic infections. In order to facilitate and model
the study of microbial infections in mice, cell culture systems
have been developed where epithelial cells form a confluent,
polarized, ciliated epithelium when grown at an air-liquid in-
terface (4). Using this model, we have previously demonstrated
that murine tracheal epithelial cells display many characteris-
tics similar to those of murine tracheal epithelium in vivo and
that these cells retain the ability ex vivo to produce important
antimicrobial molecules such as -defensins, which have been
specifically demonstrated in the trachea (4). We have also
shown previously that Defb2 is expressed in these cells after
LPS induction (4). However, we did not follow the in vivo fate
of this gene in relation to S. aureus exposure because, in vitro,
the Defb2 peptide is a very poor antimicrobial against S. aureus
FIG. 4. Ad-mediated elafin production and antibacterial activity in vitro. Female C57BL/6 mouse tracheal epithelial cells were either uninfected
or infected with Ad-LacZ control or Ad-elafin (MOI  100) in MEEM containing CaPO4 precipitates. After 18 to 20 h at 37°C (see Fig. 3 legend),
a 200-CFU inoculum of S. aureus was added (as for Fig. 2). Bacterial counts were performed as described in the same legend, and elafin
quantification was performed by ELISA (21). Values represent mean	 the standard error of three experiments, each performed in triplicate (three
inserts). ❋, Significant difference (Mann-Whitney, P  0.005); ND, not detected.
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strain C1705 (M. Rolfe et al., unpublished). Here, we have
extended these findings by showing for the first time that two
further important molecules with activity against S. aureus
(Defr1 and Defb14) are also expressed in this system. Defr1
encodes a defensin related peptide (Defr1) that deviates from
the canonical six cysteine defensin motif by having the first
cysteine replaced with a tyrosine in C57BL/6 mice (21). Sur-
prisingly, we have shown that the five cysteine Defr1 peptide is
active in vitro as an antimicrobial and has salt sensitive activity
against S. aureus. Defb14 is the mouse orthologue of human
DEFB103, which encodes a human peptide (hBD3), shown to
have potent activity against S. aureus, including MRSA (17).
However, despite the ability of these cells to secrete these
antibacterial molecules (Fig. 1), we have shown here that they
are unable to control S. aureus growth in ALI cultures (Fig. 2).
The mechanism for such resistance of S. aureus may be
complex and could be due partly to its capacity to modify
phosphatidylglycerol, the major phospholipid of S. aureus, with
L-lysine, rendering the membrane more cationic and hence
repulsive to cationic antimicrobial molecules such as defensins
(25). A more specific mechanism could be the production of
staphylokinase, which has been shown recently to inactivate
human defensins (15). Although we have not demonstrated
here the secretion of murine endogenous antimicrobial pep-
tides (and only showed their transcripts [see Fig. 1]), it is likely
that these were also produced as demonstrated for HBD-2 in
the same ALI system (35). Since it is therefore likely that S.
aureus was able to grow even in the presence of these endog-
enous peptides, we then tested whether overexpressing human
FIG. 5. Ad-elafin expression and antibacterial activity in vivo. Female C57BL/6 mice were sequentially instilled intratracheally with either Ad-LacZ
or Ad-elafin and then with S. aureus (S.a) (see Table 1). At 24 h after bacterial administration, BALF was obtained and centrifuged; the cell pellet was
used for differential cell analysis, whereas supernatants were used for bacterial counts (Mann-Whitney analysis) and elafin quantification. In parallel,
RNA was isolated from lungs and elafin RT-PCR analysis was performed as described in Materials and Methods. ND, not detected.
FIG. 6. Correlation between neutrophil count and elafin concen-
tration in BALF. BALF from mice given Ad-elafin and S. aureus (see
Table 1) were analyzed for elafin levels (by ELISA) and neutrophil
count (by using cytospins).
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elafin, a molecule for which no ortholog exists in the mouse,
would endow murine tracheal cells with defense against S.
aureus.
Here, using the Ad-overexpressing system described above,
we show that murine tracheal epithelial cells producing human
elafin were able to reduce S. aureus numbers significantly (Fig.
4). Although the exact mechanism of action was not elucidated
and was beyond the scope of the present study, the elafin
molecule has a net positive charge of 7, suggesting that its
activity against S. aureus (34) may be directed at bacterial
membranes.
We show in Fig. 4 that elafin secretion is associated with
significant inhibition of growth of S. aureus, although it is
unclear whether it acts only to slow the growth of the organ-
isms, directly kills a proportion of the organisms, or a combi-
nation of both, since the CFU counts of S. aureus recovered
after incubation with Ad-elafin-infected cells were not lower
than those added at the outset (not shown). In addition, elafin
FIG. 7. Ad-elafin treatment results in the reduction of neutrophil clusters after intratracheal administration of S. aureus in mice. The
histological appearance (magnification, 400) of representative 3-m lung sections (fixed in formalin, embedded in paraffin, and stained with
hematoxylin and eosin) is shown. (b and c) Ad-elafin–S. aureus treatment reduced the numbers of neutrophil clusters (occasional “isolated”
neutrophils were observed, see arrows) (c) compared to Ad-LacZ–S. aureus treatment, where multiple clusters were present (b, arrows). (a) None
were seen in PBS-PBS-treated animals. Corresponding neutrophil numbers from each section are shown in the relevant bar graph.
TABLE 1. Inflammatory parameters in BALF of C57BL/6 mice sequentially receiving Ad vectors and S. aureusa
Treatment No. ofmice
Content (range)
BALF protein (g/ml) BALF MPO (arbitrary units) BALF TNF (pg/ml)
PBS-PBS 3 314.7 (232.7–320.4) 0.031 (0.008–0.26) 15.0 (3.75–48.75)
Ad-LacZ–S. aureus 6 743.2 (579.3–851.6) 0.094 (0.049–0.299) 2,283.3* (975.0–3,225.0)
Ad-elafin–S. aureus 8 567.0* (433.7–689.3) 0.059 (0.027–0.165) 577.5*† (221.9–1,188.1)
a Female C57BL/6 mice received sequential intratracheal treatments of Ad-LacZ or Ad-elafin and then S. aureus as described in Materials and Methods. At 24 h
after bacterial administration, BALF was obtained and centrifuged; the cell pellet was used for differential cell analysis, whereas supernatants were used for the
determination of total protein and TNF levels and MPO activity (given as median values). *, significantly different from the PBS-PBS group; †, significantly different
from the Ad-LacZ–S. aureus group (Mann-Whitney, P 
 0.05).
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may not be acting on its own since synergy between neutrophil
defensins and cathelicidins has previously been demonstrated
against S. aureus (23). In accordance with this, although a
direct comparison between the present study and our previous
study (34) describing the incubation of synthetic elafin with S.
aureus in solution in the test tube is difficult, it seems that
“cell-derived” elafin (the present study) is more efficient than
synthetic elafin against S. aureus. Indeed, we show here that 3.5
g/ml (350 nM) can restrict the growth of 200 bacteria by 40%,
whereas 3,330 nM would be the extrapolated concentration of
synthetic elafin required to kill the same number of bacteria to
the same degree when incubated in solution in the test tube.
Having demonstrated a clear antimicrobial effect of elafin ex
vivo, we set out to investigate whether it also had a similar
effect in vivo. A total of 3  107 PFU of Ad-elafin or Ad-LacZ
(a dose demonstrated to induce no obvious inflammatory ef-
fects per se [33]) were instilled intratracheally 5 days prior to
the bacterial challenge. This protocol allowed for robust ex-
pression of elafin in the lungs (Fig. 5). Although this did not
result in an apparent increase in the expression of the other
-defensins studied here (data not shown), Ad-elafin adminis-
tration had a beneficial effect in this acute model. Indeed,
mirroring the ex vivo data presented in Fig. 4, Ad-elafin instil-
lation reduced the bacterial load in vivo (Fig. 5). Concomi-
tantly, when the Ad-elafin group was considered on its own,
there was a negative correlation between lung elafin levels and
neutrophil numbers (Fig. 6). The histological analysis of lungs
confirmed this finding and showed a reduction in the number
of neutrophilic pneumonia-like foci in the alveoli (Fig. 7). This
is reminiscent of our previous study, in which P. aeruginosa was
administered intratracheally in a protocol similar to the one
used here (33). In that study, as here (Table 1), markers of
inflammation such as BALF TNF- and MPO levels were
reduced in the Ad-elafin–plus–bacteria group. It could there-
fore be hypothesized that, in an infective situation, elafin may
act directly as a bacteriostatic or bactericidal agent, thereby
reducing the infective load. A consequence of this would be a
reduction in the cellular inflammatory response, as exemplified
by the reduction in cytokine levels, neutrophil activation, and
neutrophil-associated “collateral lung damage,” as shown by a
reduction in protein leakage in the alveolar compartment (Ta-
ble 1). Elafin could also have a further direct anti-inflammatory
function; indeed, we have shown recently that in vitro elafin
inhibits NF-B (11), an important proinflammatory transcrip-
tion factor which has been shown to be activated by S. aureus
protein A (7). Of note, the mode of action of elafin may be
different in noninfective situations, for example, when LPS is
used as an inflammatory stimulus, where elafin’s chemotactic
functions may become prominent (30, 32).
In conclusion, we demonstrated here that elafin is able to
confer an increased antimicrobial phenotype to primary mu-
rine tracheal epithelial cells which, despite the endogenous
expression of at least three -defensins (shown at the RNA
level) with in vitro relevance to S. aureus killing, were other-
wise unable to contain the growth of this pathogen in vitro.
This phenotype was replicated in vivo, in a model of acute
inflammation in C57BL/6 mice. We believe that these data
have implications both for the development of improved mu-
rine models of S. aureus lung infections and for the consider-
ation of elafin as a potential therapeutic agent against S. au-
reus-associated local and systemic infections.
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